Related Experiment Videos
Hypertension pharmacogenomics: current status and future directions
Julie A Johnson1, Stephen T Turner
1University of Florida, Departments of Pharmacy Practice and Medicine (Cardiology) and Center for Pharmacogenomics, Box 100486, Gainesville, FL 32610-0486, USA. johnson@cop.ufl.edu
Current Opinion in Molecular Therapeutics
|June 28, 2005
Summary
Pharmacogenomics can help personalize hypertension treatment by identifying genetic markers that predict drug response. Future research aims to improve blood pressure control through these genetic insights.
Area of Science:
- Pharmacogenomics
- Cardiovascular Medicine
- Genetics
Background:
- Hypertension is a prevalent chronic disease with suboptimal blood pressure control in many patients.
- Current antihypertensive therapies have limited efficacy, necessitating personalized treatment approaches.
Purpose of the Study:
- To review the current literature on hypertension pharmacogenetics.
- To identify compelling genetic candidates influencing antihypertensive drug response.
- To discuss limitations and future directions in the field.
Main Methods:
- Literature review of hypertension pharmacogenetics studies.
- Identification of genes with replicated evidence for pharmacogenetic associations.
- Analysis of study limitations and potential improvements.
Main Results:
- Few genes influencing antihypertensive response have been studied.
- Genes like alpha-adducin, beta1-adrenergic receptor, and angiotensinogen show promise.
- Current studies are limited by small sample sizes and suboptimal phenotypes.
Conclusions:
- Hypertension pharmacogenomics offers potential for improved patient management.
- Addressing limitations in study design and genetic approaches is crucial for clinical translation.
- Further research is needed to realize the clinical potential of pharmacogenomics in hypertension.